 <h1>Trazimera Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>trastuzumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about trastuzumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Trazimera.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to trastuzumab: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Administration of trastuzumab products can result in subclinical and clinical cardiac failure, with the greatest risk and severity upon concurrent administration with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue trastuzumab-dkst in patients receiving adjuvant therapy and withhold trastuzumab-dkst for a clinically significant decrease in left ventricular function. Serious and fatal infusion reactions and pulmonary toxicity may occur during or within 24 hours after administration. Discontinue trastuzumab-dkst if signs of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome are noted. Exposure during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, trastuzumab (the active ingredient contained in Trazimera) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking trastuzumab:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>cracked lips</li>
<li>decreased frequency or amount of urine</li>
<li>diarrhea</li>
<li>difficult or labored breathing</li>
<li>difficulty in swallowing</li>
<li>dry mouth</li>
<li>fever</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased blood pressure</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle aches, pain, or cramps</li>
<li>nausea</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>peeling of the skin</li>
<li>pinpoint red spots on the skin</li>
<li>seizures</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>stuffy or runny nose</li>
<li>swelling of the face, fingers, or lower legs</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody nose</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>burning or stinging of the skin</li>
<li>cloudy urine</li>
<li>dilated neck veins</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>extreme tiredness or weakness</li>
<li>fainting</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>irregular breathing</li>
<li>joint pain</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>nervousness</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>pounding in the ears</li>
<li>shivering</li>
<li>sneezing</li>
<li>sweating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chest discomfort</li>
<li>hives, itching, skin rash</li>
<li>joint stiffness or swelling</li>
<li>neck tenderness or swelling</li>
<li>redness of the skin</li>
<li>tightness in the chest</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of trastuzumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>difficulty in moving</li>
<li>feeling of warmth</li>
<li>muscle stiffness</li>
<li>redness of the face, neck, arms and occasionally, upper chest</li>
<li>sudden sweating</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acne</li>
<li>back pain</li>
<li>belching</li>
<li>bone pain</li>
<li>constipation</li>
<li>discoloration of the fingernails or toenails</li>
<li>heartburn</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>muscle spasm</li>
<li>stomach upset or pain</li>
<li>upper stomach pain</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to trastuzumab: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse events were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, stomatitis, weight loss, thrombocytopenia, mucosal inflammation, nasopharyngitis, dysgeusia, and myalgia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (78%), leukopenia (52%), anemia (36%), febrile neutropenia (23%), thrombocytopenia (16%)</p>
<p><b>Frequency not reported</b>: Hypoprothrombinemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): LVEF decrease (44%), congestive heart failure (28%), cardiomyopathy (15%), peripheral edema (10%), tachycardia (10%)</p>
<p><b>Common</b> (1% to 10%): Hypertension, hypotension, asymptomatic cardiac dysfunction, ejection fraction decreased, palpitation, cardiac arrhythmia, cardiac failure, heart beat irregular, cardiac flutter, lymphedema, hot flush, thrombotic adverse event, supraventricular tachyarrhythmia, vasodilation</p>
<p><b>Uncommon</b> (0.1% to 1%): Ventricular dysfunction, pericardial effusion</p>
<p><b>Frequency not reported</b>: Cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, S3 gallop<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (54%)</p>
<p><b>Common</b> (1% to 10%): Hypersensitivity, allergic reaction </p>
<p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylactic shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (43%), dyspnea (42%), rhinitis (22%), Grade 2 to 5 pulmonary toxicity (14%), nasopharyngitis (13%), wheezing, epistaxis, rhinorrhea</p>
<p><b>Common</b> (1% to 10%): Pharyngolaryngeal pain, sinusitis, epistaxis, upper respiratory infection, rhinitis, asthma, lung disorder, pleural effusion </p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis</p>
<p><b>Frequency not reported</b>: Pulmonary insufficiency, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary edema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased, laryngeal edema, pulmonary edema, orthopnea</p>
<p><b>Postmarketing reports</b>: Bronchospasm, hypoxia, pleural effusions, non-cardiogenic pulmonary edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (47%), herpes simplex (38%), antibody to trastuzumab (the active ingredient contained in Trazimera) (15%), flu syndrome (12%)</p>
<p><b>Common</b> (1% to 10%): Neutropenic sepsis, postoperative wound infection, herpes zoster</p>
<p><b>Uncommon</b> (0.1% to 1%): Sepsis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal impairment/failure (18%)</p>
<p><b>Common</b> (1% to 10%): Grade 3 or 4 renal failure, renal disorder, hyperbilirubinemia</p>
<p><b>Frequency not reported</b>: Glomerulonephritis membranous, glomerulonephropathy, renal failure</p>
<p><b>Postmarketing reports</b>: Nephrotic syndrome with pathological evidence of glomerulopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (76%), vomiting (53%), diarrhea (45%), abdominal pain (34%), stomatitis (24%), anorexia (14%)</p>
<p><b>Common</b> (1% to 10%): Constipation, dyspepsia, dysphagia, lip swelling, pancreatitis, hemorrhoids, dry mouth<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (44%), asthenia (42%), fatigue (35%), insomnia (29%), dizziness (24%), paresthesia (23%), peripheral neuritis (23%), neuropathy (13%), dysgeusia (10%), dizziness (13%), tremor, hypoesthesia</p>
<p><b>Common</b> (1% to 10%): Hypertonia, somnolence, ataxia</p>
<p><b>Rare</b> (less than 0.1%): Paresis</p>
<p><b>Frequency not reported</b>: Brain edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (38%), nail changes (12%), acne (11%), rash/desquamation (11%), erythema, swelling face, palmar-plantar erythrodysesthesia syndrome, alopecia</p>
<p><b>Common</b> (1% to 10%): Pruritus, dry skin, ecchymosis, hyperhidrosis, maculopapular rash, onychoclasis, dermatitis, contusion, skin infection, erysipelas, cellulitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (37%), back pain (34%), bone pain (24%), muscle tightness, myalgia </p>
<p><b>Common</b> (1% to 10%): Muscle spasm, neck pain, pain in extremity, arthritis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (31%), hypokalemia (28%), weight loss (23%)</p>
<p><b>Frequency not reported</b>: Hyperkalemia</p>
<p><b>Postmarketing reports</b>: Volume overload<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (62%), pain (61%), fever (56%), chills (41%), accidental injury (13%)</p>
<p><b>Common</b> (1% to 10%): Malaise</p>
<p><b>Uncommon</b> (0.1% to 1%): Deafness</p>
<p><b>Rare</b> (less than 0.1%): Sudden death</p>
<p><b>Postmarketing reports</b>: Oligohydramnios or oligohydramnios sequence (including pulmonary hypoplasia, skeletal abnormalities, and neonatal death)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatocellular injury, hepatitis, liver tenderness</p>
<p><b>Rare</b> (less than 0.1%): Jaundice</p>
<p><b>Frequency not reported</b>: Hepatic failure<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis, lacrimation increased</p>
<p><b>Common</b> (1% to 10%): Dry eye</p>
<p><b>Frequency not reported</b>: Papilledema, retinal hemorrhage<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Breast inflammation/mastitis, urinary tract infection, cystitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (20%), insomnia (14%)</p>
<p><b>Common</b> (1% to 10%): Anxiety, thinking abnormal</p>
<p><b>Uncommon</b> (0.1% to 1%): Depression<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Autoimmune thyroiditis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Malignant neoplasm progression, neoplasm progression<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Ogivri (trastuzumab)." Mylan GmbH, Morgantown, WV. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long can you stay on Herceptin and Perjeta?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>How long does Herceptin stay in your body?</li>
<li>What is Herceptin? Is Herceptin a chemo drug? How does it work?</li>
<li>Does Herceptin (trastuzumab) stop menstrual periods?</li>
<li>How effective is Herceptin for Breast &amp; Gastric Cancer?</li>
<li>Do Herceptin (trastuzumab) injections hurt?</li>
<li>How is Herceptin Injection and Herceptin Hylecta administered?</li>
<li>What is the difference between Ogivri and Herceptin?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Trazimera (trastuzumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: HER2 inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Trazimera &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Herceptin, Kanjinti, Ogivri, Ontruzant, Herzuma</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Breast Cancer, Adjuvant</li>
<li>Breast Cancer, Metastatic</li>
<li>Esophageal Carcinoma</li>
<li>Gastric Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to trastuzumab: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse events were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, stomatitis, weight loss, thrombocytopenia, mucosal inflammation, nasopharyngitis, dysgeusia, and myalgia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (78%), leukopenia (52%), anemia (36%), febrile neutropenia (23%), thrombocytopenia (16%)</p><p><b>Frequency not reported</b>: Hypoprothrombinemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): LVEF decrease (44%), congestive heart failure (28%), cardiomyopathy (15%), peripheral edema (10%), tachycardia (10%)</p><p><b>Common</b> (1% to 10%): Hypertension, hypotension, asymptomatic cardiac dysfunction, ejection fraction decreased, palpitation, cardiac arrhythmia, cardiac failure, heart beat irregular, cardiac flutter, lymphedema, hot flush, thrombotic adverse event, supraventricular tachyarrhythmia, vasodilation</p><p><b>Uncommon</b> (0.1% to 1%): Ventricular dysfunction, pericardial effusion</p><p><b>Frequency not reported</b>: Cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, S3 gallop<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (54%)</p><p><b>Common</b> (1% to 10%): Hypersensitivity, allergic reaction </p><p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylactic shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (43%), dyspnea (42%), rhinitis (22%), Grade 2 to 5 pulmonary toxicity (14%), nasopharyngitis (13%), wheezing, epistaxis, rhinorrhea</p><p><b>Common</b> (1% to 10%): Pharyngolaryngeal pain, sinusitis, epistaxis, upper respiratory infection, rhinitis, asthma, lung disorder, pleural effusion </p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis</p><p><b>Frequency not reported</b>: Pulmonary insufficiency, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary edema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased, laryngeal edema, pulmonary edema, orthopnea</p><p><b>Postmarketing reports</b>: Bronchospasm, hypoxia, pleural effusions, non-cardiogenic pulmonary edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (47%), herpes simplex (38%), antibody to trastuzumab (the active ingredient contained in Trazimera) (15%), flu syndrome (12%)</p><p><b>Common</b> (1% to 10%): Neutropenic sepsis, postoperative wound infection, herpes zoster</p><p><b>Uncommon</b> (0.1% to 1%): Sepsis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal impairment/failure (18%)</p><p><b>Common</b> (1% to 10%): Grade 3 or 4 renal failure, renal disorder, hyperbilirubinemia</p><p><b>Frequency not reported</b>: Glomerulonephritis membranous, glomerulonephropathy, renal failure</p><p><b>Postmarketing reports</b>: Nephrotic syndrome with pathological evidence of glomerulopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (76%), vomiting (53%), diarrhea (45%), abdominal pain (34%), stomatitis (24%), anorexia (14%)</p><p><b>Common</b> (1% to 10%): Constipation, dyspepsia, dysphagia, lip swelling, pancreatitis, hemorrhoids, dry mouth<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (44%), asthenia (42%), fatigue (35%), insomnia (29%), dizziness (24%), paresthesia (23%), peripheral neuritis (23%), neuropathy (13%), dysgeusia (10%), dizziness (13%), tremor, hypoesthesia</p><p><b>Common</b> (1% to 10%): Hypertonia, somnolence, ataxia</p><p><b>Rare</b> (less than 0.1%): Paresis</p><p><b>Frequency not reported</b>: Brain edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (38%), nail changes (12%), acne (11%), rash/desquamation (11%), erythema, swelling face, palmar-plantar erythrodysesthesia syndrome, alopecia</p><p><b>Common</b> (1% to 10%): Pruritus, dry skin, ecchymosis, hyperhidrosis, maculopapular rash, onychoclasis, dermatitis, contusion, skin infection, erysipelas, cellulitis</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (37%), back pain (34%), bone pain (24%), muscle tightness, myalgia </p><p><b>Common</b> (1% to 10%): Muscle spasm, neck pain, pain in extremity, arthritis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (31%), hypokalemia (28%), weight loss (23%)</p><p><b>Frequency not reported</b>: Hyperkalemia</p><p><b>Postmarketing reports</b>: Volume overload<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (62%), pain (61%), fever (56%), chills (41%), accidental injury (13%)</p><p><b>Common</b> (1% to 10%): Malaise</p><p><b>Uncommon</b> (0.1% to 1%): Deafness</p><p><b>Rare</b> (less than 0.1%): Sudden death</p><p><b>Postmarketing reports</b>: Oligohydramnios or oligohydramnios sequence (including pulmonary hypoplasia, skeletal abnormalities, and neonatal death)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatocellular injury, hepatitis, liver tenderness</p><p><b>Rare</b> (less than 0.1%): Jaundice</p><p><b>Frequency not reported</b>: Hepatic failure<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis, lacrimation increased</p><p><b>Common</b> (1% to 10%): Dry eye</p><p><b>Frequency not reported</b>: Papilledema, retinal hemorrhage<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Breast inflammation/mastitis, urinary tract infection, cystitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (20%), insomnia (14%)</p><p><b>Common</b> (1% to 10%): Anxiety, thinking abnormal</p><p><b>Uncommon</b> (0.1% to 1%): Depression<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Autoimmune thyroiditis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Malignant neoplasm progression, neoplasm progression<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Ogivri (trastuzumab)." Mylan GmbH, Morgantown, WV. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long can you stay on Herceptin and Perjeta?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>How long does Herceptin stay in your body?</li>
<li>What is Herceptin? Is Herceptin a chemo drug? How does it work?</li>
<li>Does Herceptin (trastuzumab) stop menstrual periods?</li>
<li>How effective is Herceptin for Breast &amp; Gastric Cancer?</li>
<li>Do Herceptin (trastuzumab) injections hurt?</li>
<li>How is Herceptin Injection and Herceptin Hylecta administered?</li>
<li>What is the difference between Ogivri and Herceptin?</li>
</ul><h2>More about Trazimera (trastuzumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: HER2 inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Trazimera &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Breast Cancer, Adjuvant</li>
<li>Breast Cancer, Metastatic</li>
<li>Esophageal Carcinoma</li>
<li>Gastric Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>